KRGGC 1992.

Methods	Multicentre RCT 2 arms
Participants	n = 60 Inoperable or metastatic gastric adenocarcinoma
Interventions	FP: cisplatin 50 mg/m²; 5‐FU 250 mg/m² on day 1; 5‐FU 250 mg/m² days 2‐5 FPEPIR: cisplatin 50 mg/m²; 5‐FU 250 mg/m² days 2‐5; epirubicin 30 mg/m² day 2
Outcomes	Response rates Overall survival Toxicity
Notes	—
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	Low risk	Sealed envelopes
Incomplete outcome data (attrition bias) efficacy	High risk	5 patients not evaluated: 3 death from PD with 4 weeks of treatment, 1 due to relocation, 1 due to absence of follow‐up exam
Incomplete outcome data (attrition bias) safety	Unclear risk	Toxic reactions classified by "standardization of reporting of results of cancer treatment" grading
Selective reporting (reporting bias)	Low risk	RR, OS, toxicity (but not CTCAE/WHO)
Other bias	Unclear risk	N/A
Blinded review of CT/MRI‐scans?	Unclear risk	Not stated